Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Executive Summary
Key strategy updates are coming: GSK will unveil its new R&D approach, Biogen will update investors on its Alzheimer's plans, and investors are keen to find out whether or not Lilly will sell its animal health franchise. Investors will also be keeping an eye on how Gilead is faring with its move into oncology.
You may also be interested in...
Pharma Q2 Results Preview: AstraZeneca, Roche, Merck And BMS
Over two days, stakeholders will get a complete picture of the checkpoint inhibitor market as the four major immuno-oncology sponsors report second quarter sales and earnings.
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.
Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.